Eczema trials recruiting in Indiana

All Eczema trials nationally

Cities in Indiana

Recruiting trials in Indiana

• A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
  NCT07558668 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Indiana: Plainfield
• A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
  NCT07277660 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: New Albany
• A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
  NCT06807281 · Phase: Phase 3 · Ages: 2 Years to 11 Years · Sex: All (male and female) · Indiana: Indianapolis
• A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
  NCT07643766 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Indianapolis, Plainfield
• A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
  NCT07599813 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Indiana: Clarksville, Indianapolis
• A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
  NCT05995964 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Indiana: Indianapolis, New Albany
• A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
  NCT06389136 · Phase: Phase 3 · Ages: 18 Years to 63 Years · Sex: All (male and female) · Indiana: Indianapolis, West Lafayette
• A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
  NCT06807268 · Phase: Phase 3 · Ages: 6 Years to 11 Years · Sex: All (male and female) · Indiana: Indianapolis
• A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
  NCT06461897 · Phase: Phase 3 · Ages: 2 Years to 11 Years · Sex: All (male and female) · Indiana: Indianapolis
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
  NCT06241118 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Indiana: Indianapolis
• Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
  NCT07453602 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Indiana: Plainfield
• Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
  NCT06988605 · Phase: Not specified · Ages: 12 Years and older · Sex: All (male and female) · Indiana: Indianapolis, West Lafayette
• Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
  NCT07298395 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Indiana: Clarksville, New Albany, West Lafayette